BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $21.66 million. The enterprise value is -$27.39 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 58.02 million shares outstanding. The number of shares has increased by 1.19% in one year.
| Current Share Class | 58.02M |
| Shares Outstanding | 58.02M |
| Shares Change (YoY) | +1.19% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 6.76% |
| Owned by Institutions (%) | 26.59% |
| Float | 41.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.64 |
| Forward PS | n/a |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.37
| Current Ratio | 3.37 |
| Quick Ratio | 3.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -164.30% and return on invested capital (ROIC) is -105.76%.
| Return on Equity (ROE) | -164.30% |
| Return on Assets (ROA) | -53.71% |
| Return on Invested Capital (ROIC) | -105.76% |
| Return on Capital Employed (ROCE) | -195.19% |
| Revenue Per Employee | $169,231 |
| Profits Per Employee | -$1.07M |
| Employee Count | 65 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.21% in the last 52 weeks. The beta is 1.18, so BioAtla's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -89.21% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 1.30 |
| Relative Strength Index (RSI) | 48.47 |
| Average Volume (20 Days) | 713,361 |
Short Selling Information
The latest short interest is 4.22 million, so 7.28% of the outstanding shares have been sold short.
| Short Interest | 4.22M |
| Short Previous Month | 3.18M |
| Short % of Shares Out | 7.28% |
| Short % of Float | 10.07% |
| Short Ratio (days to cover) | 4.54 |
Income Statement
In the last 12 months, BioAtla had revenue of $11.00 million and -$69.78 million in losses. Loss per share was -$1.44.
| Revenue | 11.00M |
| Gross Profit | 11.00M |
| Operating Income | -73.94M |
| Pretax Income | -104.56M |
| Net Income | -69.78M |
| EBITDA | -73.01M |
| EBIT | -73.94M |
| Loss Per Share | -$1.44 |
Full Income StatementBalance Sheet
The company has $49.05 million in cash and n/a in debt, giving a net cash position of $49.05 million or $0.85 per share.
| Cash & Cash Equivalents | 49.05M |
| Total Debt | n/a |
| Net Cash | 49.05M |
| Net Cash Per Share | $0.85 |
| Equity (Book Value) | 14.27M |
| Book Value Per Share | 0.30 |
| Working Capital | 34.51M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -672.21% |
| Pretax Margin | -634.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |